AngioDynamics (ANGO, Financial) has released its financial forecast for the fiscal year 2026, anticipating adjusted earnings per share to range between 30 cents and $3.25. The company expects revenue to fall between $305 million and $310 million, slightly above the market consensus of approximately $304.86 million.
Tariff-related adjustments play a significant role in these projections. The anticipated impact from tariffs is estimated to be between $4.0 million and $6.0 million. In terms of gross margin, pro forma adjusted EBITDA, and adjusted EPS, the lower end of the forecast ranges assumes the maximum impact from tariffs, while the upper end assumes minimal tariff impact.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 3 analysts, the average target price for AngioDynamics Inc (ANGO, Financial) is $15.67 with a high estimate of $16.00 and a low estimate of $15.00. The average target implies an upside of 62.69% from the current price of $9.63. More detailed estimate data can be found on the AngioDynamics Inc (ANGO) Forecast page.
Based on the consensus recommendation from 3 brokerage firms, AngioDynamics Inc's (ANGO, Financial) average brokerage recommendation is currently 1.7, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for AngioDynamics Inc (ANGO, Financial) in one year is $8.26, suggesting a downside of 14.23% from the current price of $9.63. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the AngioDynamics Inc (ANGO) Summary page.
